# US 2020/0289469 A1 · Arginine methyltransferase inhibitors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0289469 A1
- Document ID: US20200289469A1
- Status: Published application
- Kind: A1
- Application number: 16/801,290
- Filed: 2020-02-26
- Published: 2020-09-17
- Earliest claimed: 2013-03-14
- Assignees: Epizyme, Inc.
- Applicants: Epizyme, Inc.
- Inventors: Richard Chesworth; Lorna Helen Mitchell; Gideon Shapiro
- Web page: https://patentgrep.com/patent/US20200289469A1

## CPC

- A61K 31/415: 1,2-Diazoles
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- C07D 231/10: having two or three double bonds between ring members or between ring members and non-ring members
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 401/02: containing two hetero rings
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/02: containing two hetero rings
- C07D 413/08: linked by a carbon chain containing alicyclic rings
- C12N 9/1007: {Methyltransferases (general) (2.1.1.)}
- C12Y 201/01125: Histone-arginine N-methyltransferase (2.1.1.125)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

## Claims

### Claim at position 1

1-75. (canceled)

### Claim 76

A compound of Formula (II):
or a pharmaceutically acceptable salt thereof,
wherein
L1 is a bond;
R3 is hydrogen, C1-4 alkyl, or C3-4 cycloalkyl;
R4 is hydrogen or optionally substituted C1-6 alkyl;
R5 is hydrogen or optionally substituted C1-4 alkyl;
Rx is optionally substituted C1-4 alkyl or optionally substituted C3-4 cycloalkyl; and
RW is optionally substituted carbocyclyl or optionally substituted heterocyclyl.

### Claim 77 (depends on 76)

The compound or salt of claim 76, wherein R3 is C1-4 alkyl.

### Claim 78 (depends on 77)

The compound or salt of claim 77, wherein R3 is methyl.

### Claim 79 (depends on 76)

The compound or salt of claim 76, wherein R4 is hydrogen.

### Claim 80 (depends on 76)

The compound or salt of claim 76, wherein R5 is hydrogen.

### Claim 81 (depends on 76)

The compound or salt of claim 76, wherein Rx is methyl.

### Claim 82 (depends on 76)

The compound or salt of claim 76, wherein RW is substituted cyclohexyl.

### Claim 83 (depends on 76)

The compound or salt of claim 76, wherein RW is optionally substituted heterocyclyl.

### Claim 84 (depends on 83)

The compound or salt of claim 83, wherein the heterocyclyl is monocyclic or bicyclic.

### Claim 85 (depends on 76)

The compound of claim 76, wherein R3 is methyl, R4 is hydrogen, R5 is hydrogen, Rx is methyl, and RW is substituted cyclohexyl.

### Claim 86 (depends on 76)

The compound or salt of claim 76, selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 87 (depends on 76)

A pharmaceutical composition comprising a compound of claim 76, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 88 (depends on 76)

A method of inhibiting an arginine methyl transferase (RMT) comprising contacting a cell with an effective amount of a compound of claim 76, or a pharmaceutically acceptable salt thereof.

### Claim 89 (depends on 76)

A method of modulating gene expression or transcription comprising contacting a cell with an effective amount of a compound of claim 76, or a pharmaceutically acceptable salt thereof.

### Claim 90 (depends on 76)

A method of treating a RMT-mediated disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 76, or a pharmaceutically acceptable salt thereof.

### Claim 91 (depends on 90)

The method of claim 90, wherein the RMT-mediated disorder is a PRMT1-mediated disorder, a PRMT6-mediated disorder, a PRMT3-mediated disorder, a PRMT8-mediated disorder, or a CARM1-mediated disorder.

### Claim 92 (depends on 91)

The method of claim 91, wherein the disorder is a proliferative disorder, a neurological disorder, a muscular dystrophy, an autoimmune disorder, a vascular disorder, or a metabolic disorder.

### Claim 93 (depends on 91)

The method of claim 91, wherein the disorder is diabetes mellitus, kidney failure, coronary heart disease, oculopharyngeal muscular dystrophy, or amyotrophic lateral sclerosis.

### Claim 94 (depends on 91)

The method of claim 91, wherein the disorder is cancer.

### Claim 95 (depends on 94)

The method of claim 94, wherein the cancer is breast cancer, pancreatic cancer, prostate cancer, lung cancer, non-small cell lung cancer (NSCLC), colon cancer, bladder cancer, lymphoma, diffuse large B-cell lymphoma (DLBCL), leukemia, or acute myelocytic leukemia (AML).
